Work

[The efficacy and safety of ibrutinib in the treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].

Year: 2024

Type: other

Abstract: Ibrutinib exhibits good efficacy and safety for newly treated and R/R LPL/WM patients.

Source: PubMed

DOI: 10.3760/cma.j.cn121090-20240301-00077

Authors: Y S Huang, W J Xiong, J J Yuan, Y Yu, Y X Li, Y T Yan, T Y Wang, R Lyu, W Liu, G An, Y Z Zhao, D H Zou, L G Qiu, S H Yi

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Natural Science Foundation of China

Award: G8325313504

OpenAlex ID: W4402755012

Cites:

Cited by:

Related to: 10